Approval · Notice of Compliance 27855 · 2022
TECENTRIQ: Notice of Compliance 27855
Issued March 29, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 27855
- Date
- March 29, 2022
- Company
- Hoffmann-La Roche LimitedMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Removal of NOC/c indication : for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who: Have disease progression during or following platinumcontaining chemotherapy; or Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinumcontaining chemotherapy
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TECENTRIQ | Not yet assigned | — |
Medicinal ingredients
- ATEZOLIZUMAB 1,200 MG per 20ML
- ATEZOLIZUMAB 840 MG per 14ML